Episode
🤖 Anthropic Is Making Its Own Drugs — And That's Just the Start
- Published
- Jul 4, 2026
- Duration seconds
- 461
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/4bf6b545
Actions
POST https://stenobird.com/v1/public/podcasts/ai-news-podcast-latest-ai-news-analysis-events-daily-inference-7298177/episodes/anthropic-is-making-its-own-drugs-and-that-s-just-the-start/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/ai-news-podcast-latest-ai-news-analysis-events-daily-inference-7298177/anthropic-is-making-its-own-drugs-and-that-s-just-the-start.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
AI just got a lot more complicated. Anthropic is pivoting hard into pharmaceutical development while simultaneously negotiating a custom chip deal with Samsung — signaling a new era of vertical integration that goes far beyond chatbots. OpenAI's Sam Altman is reportedly pushing to hand five percent of the company's equity to a US sovereign wealth fund, raising urgent questions about who really benefits from the AI wealth explosion. In the UK, authorities are sounding the alarm for parents everywhere, warning that AI-powered 'nudification' apps are being used to exploit children's publicly posted photos in deeply disturbing ways. The question of whether human or AI-generated writing can even be told apart is no longer theoretical — it's now landing in courtrooms, newsrooms, and literary circles. Meanwhile, at Google DeepMind, employees trying to unionize are hitting walls, and a broader philosophical debate is gaining traction: has AI's ethical direction already been quietly decided by financial incentives, long before the rest of us got a vote? Subscribe to Daily Inference: dailyinference.com Love AI? Check out our other AI tools: 60sec.site and Artificial Intelligence Radio